Adcetris is indicated for the treatment of adult patients with CD30+ Hodgkin Lymphoma (HL) at increased risk of relapse or progression following Autologous Stem Cell Transplant (ASCT)

Subtype:

Hodgkin Lymphoma (HL)

License:

EMA

Class:

CD30 ADC

R/R

SmPChttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf 

1. Approved Labelling 

Adcetris is indicated for the treatment of adult patients with CD30+ Hodgkin Lymphoma (HL) at increased risk of relapse or progression following Autologous Stem Cell Transplant (ASCT).

2. Treatment Regimen

Brentuximab vedotin should be administered under the supervision of a physician experienced in the use of anti-cancer agents.

The recommended starting dose for the retreatment of patients with relapsed or refractory HL is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks. Alternatively, treatment may be started at the last tolerated dose.

Brentuximab vedotin must not be administered as an intravenous push or bolus. Brentuximab vedotin should be administered through a dedicated intravenous line and it must not be mixed with other medicinal products.

3. AE/Warnings

Please see section 4.4 of SmPC

 

 

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.